RVPH - REVIVA PHARMACEUTICALS HOLDINGS, INC.

0.6
0.070   11.667%

Share volume: 859,513
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.53
0.07
0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 0%
Dept financing 50%
Liquidity 39%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
6.48%
1 Month
-48.28%
3 Months
-67.91%
6 Months
-48.72%
1 Year
-83.47%
2 Year
-87.07%
Key data
Stock price
$0.60
P/E Ratio 
0.00
DAY RANGE
$0.48 - $0.62
EPS 
-$0.51
52 WEEK RANGE
$0.48 - $4.28
52 WEEK CHANGE
-$83.52
MARKET CAP 
42.937 M
YIELD 
N/A
SHARES OUTSTANDING 
29.817 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.12
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,844,204
AVERAGE 30 VOLUME 
$918,779
Company detail
CEO: Laxminarayan Bhat
Region: US
Website: revivapharma.com
Employees: 5
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia. RP1208 that is in pre-clinical development studies for depression and obesity.

Recent news
loading